Quick Answer
NIKA PHARMACEUTICALS, INC reported Operating Income Loss of -$76.4 thousand for the year ending 2025.
- NIKA PHARMACEUTICALS, INC showed an increase of +20.2% in Operating Income Loss from 2024 to 2025.
- This data is from NIKA PHARMACEUTICALS, INC's annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), NIKA PHARMACEUTICALS, INC's Operating Income Loss has declined by 757.7%.
- Historical annual values: Fiscal year 2025: -$76.4 thousand | Fiscal year 2024: -$95.8 thousand | Fiscal year 2023: -$64.8 thousand | Fiscal year 2022: -$3.18 million | Fiscal year 2021: -$14.7 thousand | Fiscal year 2020: -$8.9 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: